SNV in TP53, found in the primary treatment-naïve tumor in TNBC11, and MCL1 amplifications in the primary treatment-naïve tumors in TNBC11 and TNBC84, suggest that these alterations are early events in TNBC carcinogenesis. Here, TP53 is linked to neoplasm.